ABSTRACT
Streptokinase treatment was carried out in the intensive care unit of III Internal Clinic, the Higher Medical Institute--Plovdiv, on 54 patients, 51 of them with acute myocardial infarction (AMI) and 3 with intermediary coronary syndrome, making use of the preparations streptase (GFR) and avelysin (GDR). A control group of 35 patients with AMI was used. The treatment was initiated with stream administration of heparin 10,000 U and urbazon 20 mg, whereafter streptokinase 1,250,000 U per 1 h was included on that background. The results were determined according to ECG in 30 leads, recorded by 2, 4, 6, 12 and 24 h, according to creatine-phosphokinase activity and the outcome of the disease. The treatment was uninterrupted up to 24 h with the determination of the individual fibrinolytic activity. Normalization of S-T segment was established by 4 h with restoration of ECG in 10 patients, and in the rest--maintaining QS or QR forms. Re-perfusion arrhythmias were observed in 66.67% and data about re-thrombosis--in 13.61%. Lethality was 5.89%. The method is emphasized to be a reliable means for the treatment of AMI.
Subject(s)
Angina Pectoris/drug therapy , Angina, Unstable/drug therapy , Myocardial Infarction/drug therapy , Streptokinase/therapeutic use , Adult , Aged , Anticoagulants/therapeutic use , Drug Evaluation , Drug Therapy, Combination , Female , Heparin/therapeutic use , Humans , Infusions, Intravenous , Male , Methods , Methylprednisolone/therapeutic use , Middle Aged , Time FactorsABSTRACT
The results from the administration of verapamyl (isoptine--Knoll GFR) to 30 patients with disturbed heart rhythm are presented, that are grouped as follows: supraventricular paroxysmal tachycardia (SPI)--10; auricular fibrillation (AFi)--8; auricular flutter (AFl)--7; supraventricular extrasystoles (SE)--4, and ventricular extrasystoles (VE)--1. Generally, very good results were obtained, the best effect established with SPT and AFi--rhythm restored in 70 per cent, 50 per cent respectively. Improvement was not attained in a total of 26,7 per cent, adverse effects--hypotony and AV-block were established in 6,66%.
Subject(s)
Arrhythmias, Cardiac/drug therapy , Verapamil/therapeutic use , Adolescent , Adult , Aged , Blood Pressure/drug effects , Drug Evaluation , Heart Rate/drug effects , Humans , Injections, Intravenous , Middle Aged , Pulse/drug effects , TabletsSubject(s)
Fibrinolysis , Animals , Blood Coagulation , Blood Proteins/metabolism , Cardiovascular Diseases/physiopathology , Factor XIII/metabolism , Fibrin/metabolism , Fibrin Fibrinogen Degradation Products/metabolism , Fibrinogen/metabolism , Fibrinolysin/metabolism , Hemostasis , Heparin/blood , Humans , Hydrolysis , Plasminogen/metabolism , Thrombosis/etiology , Thrombosis/physiopathologyABSTRACT
The results from the treatment of cardiac rhythm disorders with mexitil are reported: 26 cases with ventricular extrasystoles, 3--with ventricular paroxysmal tachycardia, 2--with supraventricular paroxysmal tachycardia, 1--with auricular extra-systoles, 7--with combined rhythm disorders in patients with ischemic heart diseases mainly. Very good treatment effect was observed in 24 patients, good--in 7, insignificant--in 3 and no effect--in 2 patients. Mexitil was concluded to be an antiarrhythmic drug with a good tolerance and well manifested therapeutic effect, mainly in ventricular rhythm disorders.
